ConductScience.org, home

Paper32101663

Pembrolizumab for Early Triple-Negative Breast Cancer.

Schmid P and 21 others. N Engl J Med, 2020. Cited by 2,618 papers, by iCite.

Cite this record

ConductScience Library. Pembrolizumab for Early Triple-Negative Breast Cancer. Papers, record 32101663. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32101663

Download JSON
Disease
breast cancer1,032 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Pembrolizumab for Early Triple-Negative Breast Cancer.
PubMed
Journal
N Engl J Med
PubMed
Year
2020
PubMed
Publication types
Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
2,618
iCite
Relative citation ratio, by iCite
117
iCite
Revised in PubMed
2026-05-18
PubMed

Authors22

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Schmid PPeter
2Cortes JJavier
3Pusztai LLajos
4McArthur HHeather
5Kümmel SSherko
6Bergh JJonas
7Denkert CCarsten
8Park YHYeon Heehttps://orcid.org/0000-0003-4156-9212
9Hui RRina
10Harbeck NNadia
11Takahashi MMasatohttps://orcid.org/0000-0002-6641-9598
12Foukakis TTheodoroshttps://orcid.org/0000-0001-8952-9987
13Fasching PAPeter A
14Cardoso FFatima
15Untch MMichael
16Jia LLiyi
17Karantza VVassiliki
18Zhao JJing
19Aktan GGursel
20Dent RRebecca

Source PubMed

See all 22 authorsDownload CSV of authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, Monoclonal, HumanizedMajor topic
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Triple Negative Breast NeoplasmsMajor topic
Adult
Aged
Aged, 80 and over
Carboplatin
Cyclophosphamide
Doxorubicin
Epirubicin
Female
Humans
Intention to Treat Analysis
Kaplan-Meier Estimate
Middle Aged
Neoadjuvant Therapy
Neoplasm Staging
Paclitaxel

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
N/AMerck Sharp and DohmeInternationalPubMed

Source PubMed

Download CSV of grants

Trials16

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT03036488
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)
Derived from the trialYesClinicalTrials.gov
NCT05132504Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic CancerBackgroundClinicalTrials.gov
NCT05213312Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCCBackgroundClinicalTrials.gov
NCT05275777A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast CancerBackgroundClinicalTrials.gov
NCT05763992Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 TrialResultsClinicalTrials.gov
NCT05843292Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast CancerBackgroundClinicalTrials.gov
NCT06225284Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer PatientsBackgroundClinicalTrials.gov
NCT06245889PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBCResultsClinicalTrials.gov
NCT06497322Exercise Intervention in Women Diagnosed With Triple-negative Breast Cancer Receiving Oncologic TreatmentResultsClinicalTrials.gov
NCT06610097TNBC Gut Microbiota During Neoadjuvant TreatmentBackgroundClinicalTrials.gov
NCT06638931Agnostic Therapy in Rare Solid TumorsBackgroundClinicalTrials.gov
NCT07007169Mediterranean Diet and Inequality in Early Breast CancerBackgroundClinicalTrials.gov
NCT07188246Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast CancerBackgroundClinicalTrials.gov
NCT07394387Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.BackgroundClinicalTrials.gov
NCT07644455Percutaneous Biopsy After Neoadjuvant Chemotherapy.ResultsClinicalTrials.gov
NCT07743190
A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)
BackgroundClinicalTrials.gov

Download CSV of trials

Comments and corrections5

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in32127649Moving pembrolizumab forwards.https://conductscience.org/library/papers/32127649PubMed
Comment in32145769Pembrolizumab for triple-negative breast cancer.https://conductscience.org/library/papers/32145769PubMed
Comment in32561940[Pembrolizumab as neoadjuvant treatment of early triple-negative breast cancer].https://conductscience.org/library/papers/32561940PubMed
Comment in32579834Pembrolizumab for Early Triple-Negative Breast Cancer.https://conductscience.org/library/papers/32579834PubMed
Comment in36152640Toxicity and Timing of Breast Radiation Therapy With Overlapping Systemic Therapies.https://conductscience.org/library/papers/36152640PubMed

Download CSV of comments and corrections

Cited by1,895

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2,618 citations.

PMIDTitleJournalYearIn PapersSource
42983499T cell exhaustion in cancer: from functional decline to adaptive immune regulation.Mol Cancer2026https://conductscience.org/library/papers/42983499PubMed
42972023Early temporal transcriptional and cytokine responses distinguish chemotherapy sensitivity in patient-derived xenograft models of triple-negative breast cancer.Oncogene2026https://conductscience.org/library/papers/42972023PubMed
42967914Neoadjuvant concurrent or sequential anthracycline-containing chemotherapy and HER2-targeted agents for HER2-positive breast cancer: a randomized phase 2 study (METIS).Signal Transduct Target Ther2026https://conductscience.org/library/papers/42967914PubMed
42964829Non-invasive electromagnetic fields induce anti-tumor neutrophil reprogramming and enhance checkpoint blockade in breast cancer.Front Immunol2026https://conductscience.org/library/papers/42964829PubMed
42957928Direct medical costs of breast cancer by subtype and stage in Korea: a patient-level retrospective cohort analysis.Health Econ Rev2026https://conductscience.org/library/papers/42957928PubMed
42948616Ductal Carcinoma In Situ With Microinvasion Arising in a Breast Hamartoma: A Case Report and Review of Guidelines of Hamartoma Management.Case Rep Surg2026https://conductscience.org/library/papers/42948616PubMed
42947999Dual PD-1/LAG-3 Blockade in Breast Cancer: Navigating Benefit and Risk.Cancer Innov2026https://conductscience.org/library/papers/42947999PubMed
42939797Subtype-Conditioned NRF2-KEAP1 Signaling in Breast Cancer: A Narrative Review and Hypothesis-Generating Framework from Chemoprevention to Therapy Resistance.Antioxidants (Basel)2026https://conductscience.org/library/papers/42939797PubMed
42938904Cancer Cell Metabolic Reprogramming: Dietary, Pharmacological Strategies and Clinical Perspectives.Cancers (Basel)2026https://conductscience.org/library/papers/42938904PubMed
42938872Real-World Feasibility, Toxicity, and Early Outcomes of Neoadjuvant Pembrolizumab-Based Systemic Therapy in Early Triple-Negative Breast Cancer: A Single-Centre Chinese Cohort from Hong Kong.Cancers (Basel)2026https://conductscience.org/library/papers/42938872PubMed
42938804MRI-Based Prediction of Immunotherapy Response in Breast Cancer: A Systematic Review.Cancers (Basel)2026https://conductscience.org/library/papers/42938804PubMed
42936250Precision immuno-oncology in triple-negative breast cancer: from PD-L1 to multimodal biomarkers, ADC-ICI combinations, and global real-world integration.Front Immunol2026https://conductscience.org/library/papers/42936250PubMed
42931983Efficacy and toxicity for pembrolizumab-containing therapy in older adults with triple-negative breast cancer: insights from routine oncology practice.Breast Cancer Res Treat2026https://conductscience.org/library/papers/42931983PubMed
42931078Pesticide Exposure and Breast Cancer: Molecular Mechanisms, Epidemiological Evidence, and Current Challenges.J Xenobiot2026https://conductscience.org/library/papers/42931078PubMed
42930156Real-World Treatment Utilization and Patterns of Adjuvant Olaparib for Early-Stage Breast Cancer: Insights from the Komodo Research Database.Curr Oncol2026https://conductscience.org/library/papers/42930156PubMed
42930141Cardiotoxicity of Immune Checkpoint Inhibitors with Anthracycline Chemotherapy in Triple-Negative Breast Cancer.Curr Oncol2026https://conductscience.org/library/papers/42930141PubMed
42927318A HALF CENTURY OF PROGRESS IN BREAST CANCER: WHERE DO WE GO NEXT?Trans Am Clin Climatol Assoc2026https://conductscience.org/library/papers/42927318PubMed
42919392Unraveling the use of vaccine therapy in HER2-positive breast cancer: a comprehensive review of current state and future perspectives.J Exp Clin Cancer Res2026https://conductscience.org/library/papers/42919392PubMed
42903114
PD-1/PD-L1 inhibitors combined with chemotherapy or as monotherapy versus chemotherapy alone or observation in triple-negative breast cancer: a systematic review and updated meta-analysis incorporating long-term survival data.
Front Immunol2026https://conductscience.org/library/papers/42903114PubMed
42886323Neoadjuvant Chemo-Immunotherapy Yields Survival Comparable to Upfront Surgery in Metaplastic Breast Cancer: A National Cancer Database Analysis.Ann Surg Oncol2026https://conductscience.org/library/papers/42886323PubMed

See all 1,895 cited byDownload CSV of cited by

Drugs8

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
CYCLOPHOSPHAMIDECHEMBL1200796Results2https://conductscience.org/library/drugs/CHEMBL1200796ChEMBL
CARBOPLATINCHEMBL1351Results2https://conductscience.org/library/drugs/CHEMBL1351ChEMBL
CAPECITABINECHEMBL1773Results1https://conductscience.org/library/drugs/CHEMBL1773ChEMBL
PEMBROLIZUMABCHEMBL3137343Results2https://conductscience.org/library/drugs/CHEMBL3137343ChEMBL
EPIRUBICINCHEMBL417Derived from the trial1https://conductscience.org/library/drugs/CHEMBL417ChEMBL
PACLITAXELCHEMBL428647Results2https://conductscience.org/library/drugs/CHEMBL428647ChEMBL
OLAPARIBCHEMBL521686Results1https://conductscience.org/library/drugs/CHEMBL521686ChEMBL
DOXORUBICINCHEMBL53463Results2https://conductscience.org/library/drugs/CHEMBL53463ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • References
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32101663

GET https://conductscience.org/api/papers/v1/32101663/authors?page=2